Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan; Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
Diagn Microbiol Infect Dis. 2013 Nov;77(3):254-7. doi: 10.1016/j.diagmicrobio.2013.07.012. Epub 2013 Sep 9.
Vancomycin-resistant (VR) enterococci (VRE) are increasingly important nosocomial pathogens, commonly causing catheter-related urinary tract infections or vascular catheter-related bloodstream infections. In this study, 10 Enterococcus faecium and 9 Enterococcus faecalis different pulsed-field gel electrophoresis genome-type VR clinical isolates were detected. The potential role of fosfomycin-based combination regimens for biofilm-related VRE infection is in vitro evaluated. Anti-VRE activities of fosfomycin, ampicillin, linezolid, minocycline, rifampicin, tigecycline, teicoplanin, vancomycin alone, or fosfomycin-based combinations were studied by time-kill method and a biofilm model. Of the fosfomycin-based combinations, a synergistic effect was particularly noted for teicoplanin against 89% of the VR E. faecalis isolates. In a biofilm model, only linezolid alone was able to reduce the bacterial loads, and the use of fosfomycin-based combinations, excluding rifampicin (40%), failed to enhance antibacterial activity against VR E. faecium. For E. faecalis, an inhibitory effect was evident using ampicillin alone or fosfomycin plus rifampicin (100%), tigecycline (56%), or teicoplanin (44%). However, an antagonistic effect was found for ampicillin plus fosfomycin against 2 of 3 of the VR E. faecalis isolates. The antibacterial activities of the drugs tested against VRE in vitro varied by species. Ampicillin exhibited potential activity against planktonic- and biofilm-embedded VR E. faecalis. Fosfomycin-based combinations may have enhanced antibacterial effects against VRE even in the biofilm model, and this observation warrants further clinical studies.
万古霉素耐药(VR)肠球菌(VRE)是日益重要的医院获得性病原体,通常导致导管相关尿路感染或血管导管相关血流感染。在这项研究中,检测到 10 株屎肠球菌和 9 株粪肠球菌不同脉冲场凝胶电泳基因组型 VR 临床分离株。体外评估了磷霉素为基础的联合方案治疗生物膜相关 VRE 感染的潜力。采用时间杀菌法和生物膜模型研究了磷霉素、氨苄西林、利奈唑胺、米诺环素、利福平、替加环素、替考拉宁、万古霉素单独或磷霉素为基础的联合方案对 VRE 的抗药性。在磷霉素为基础的联合方案中,替考拉宁对 89%的 VR 粪肠球菌分离株表现出特别显著的协同作用。在生物膜模型中,只有利奈唑胺单独能够降低细菌负荷,而除利福平(40%)以外的磷霉素为基础的联合方案未能增强对 VR 屎肠球菌的抗菌活性。对于粪肠球菌,氨苄西林单独或磷霉素加利福平(100%)、替加环素(56%)或替考拉宁(44%)均能显著抑制生物膜内的细菌。然而,在 3 株 VR 粪肠球菌分离株中的 2 株中,发现氨苄西林加磷霉素存在拮抗作用。在体外,不同药物对 VRE 的抗菌活性因种属而异。氨苄西林对浮游生物和生物膜内嵌入的 VR 粪肠球菌表现出潜在的活性。磷霉素为基础的联合方案可能对生物膜模型中的 VRE 具有增强的抗菌作用,这一观察结果值得进一步的临床研究。